Skip to Main Content

South Carolina life Sciences

  • sam patrick posted an article
    Minority med students get a boost see more

    Courtesy of GSA Business Report

    Minority medical students will have a chance to take advantage of a $45,000 annual scholarship at the University of South Carolina School of Medicine Greenville for the next 10 years thanks to a recent grant from The BlueCross BlueShield of South Carolina Foundation and the Levi S. Kirkland Sr., M.D. Society.

    The total $3.7 million Levi S. Kirkland Sr., M.D. grant will ultimately support 21 students during four years of study at the school with the intention of boosting numbers of underrepresented populations in the field. Patients are 19 to 26 times more likely to seek care from a physician who looks like them and has similar life experiences, according to the news release.

    “The Levi S. Kirkland Sr., M.D. Society is a business resource that focuses on mentorship, sponsorship and engaging the community,” Dr. Frank Clark, president of the Levi S. Kirkland Sr., M.D. Society, said in the news release. Clark is clinical assistant professor at the University of South Carolina School of Medicine Greenville and medical director and division chief for adult inpatient and consultation-liaison services at Prisma Health−Upstate. “It’s vitally important, as we serve our communities, that we have a diverse physician workforce.”

    The 10-year grant, named after the first Black physician to work in the Greenville Health System, now known as Prisma Health, is the longest-running grant in the foundation’s history and was gifted after the University of South Carolina School of Medicine accepted its most diverse student population yet with a 24% minority cohort, the release said.

    The school projects that number to rise to 26% for the 2021 class, according to the release.

    “We are thrilled at the opportunities that this grant will provide for our students,” Dr. Marjorie Jenkins, school dean and chief academic officer at Prisma Health−Upstate, said in the release. “This generous grant from the foundation is an important investment in our students and a testament to the excellent medical education we provide to future physicians for the Upstate and across South Carolina.”

    Students who receive the scholarship must agree to practice medicine in the Palmetto State for four years.

    “One of the biggest worries of medical school is finances, tuition and living expenses,” Dillon Isaac, a medical student at the school and past scholarship recipient, said in the release. “Because of this scholarship, all of my efforts can go into studying medicine, addressing health care disparities, and looking into social determinants of health. Altogether, this will help me give my overall best toward patient care and give back to the community that raised me. With that, I’m extremely excited to share I’ll be continuing my medical training as an internal medicine-pediatrics resident in the Upstate. I’m so excited to follow in the footsteps of the physicians that continuously support and inspire me.”

  • sam patrick posted an article
    Erin Ford named SCBIO Interim CEO as Konduros accepts private sector position see more

    Exiting CEO credited with reinvigorating organization, building team and investor base to “take South Carolina life sciences to an entirely new level”; SCBIO to conduct national search for new CEO

     

    SOUTH CAROLINA – April 7, 2021SCBIO Chief Executive Officer Sam Konduros – who has led the rejuvenation of South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, innovating and growing the life sciences industry in the Palmetto State for four years – is stepping down from his current role in May to pursue “an extraordinary private sector opportunity in the life sciences and healthcare space,” the organization’s Board of Directors has announced.

    Konduros is departing SCBIO to serve on the Board of Directors of Charleston-headquartered Vikor Scientific, and as Chief Executive Officer of a new health innovation company focused on delivering a novel blueprint to the healthcare marketplace, powered by AI and blockchain technologies and focused on science-based personalized medicine strategies to solve some of the nation’s most pressing healthcare challenges.  The soon-to-be identified organization will be revealed in May 2021 and will be part of the Vikor Scientific growing portfolio of companies.  Vikor Scientific, led by co-Founders Scotty Branch and Shea Harrelson, is a prominent national brand among SCBIO’s Board and 140+ investors and organizational members, that has experienced explosive growth over the past 3 years.

    Konduros is working closely with SCBIO’s board leadership on a carefully designed transition strategy.  SCBIO’s world class board – comprised of top executives from industry, economic development, healthcare, research, government and higher education – will begin the search for Konduros’ successor immediately with SCBIO Executive Vice President and Chief Operating Officer Erin Ford assuming day-to-day responsibilities and reporting to the board once Konduros officially departs in early May.

    “Sam Konduros has been a force – for economic development, for life sciences and for the long-term prosperity of South Carolina,” said SCBIO Board of Directors Chair Lou Kennedy, also the CEO of Nephron Pharmaceuticals.  “It has been an honor to work with him, he has made a remarkable impact on this organization, and he leaves it better than he found it, as one of the most influential associations in the state. We thank Sam for the service and sacrifice he has given to SCBIO, and we wish him all the best.”

    As Executive Vice President and Chief Operating Officer, Ms. Ford has served as primary lead for SCBIO’s business operations and finances, championing investor relations and existing industry strategies, and spearheading integrated marketing initiatives.  She has managed the majority of the organization’s day-to-day requirements since joining SCBIO in 2017.  She will assume the role of Interim CEO of SCBIO effective May 1st.

    “Serving as President and CEO of SCBIO has been a true honor, and one of the great highlights of my career to date.  It is bittersweet to depart in the midst of such incredible progress, but the organization has never been on more solid footing with strong finances, an amazing team, and a world-class Board of Directors to lead it forward.  I will remain committed to its success for years to come in my new role, as I directly join the beloved industry that I have striven to serve and support in recent years.  I am beyond grateful to SCBIO’s Board and to my new employer, Vikor Scientific, for the extraordinary opportunities that I’ve received,” said Konduros.

    During Konduros’ tenure, SCBIO has more than doubled membership and quadrupled revenues, implemented a strong economic development focus, and launched a new innovation platform.  It also expanded its role as the voice of the life sciences industry, implemented a surging workforce development initiative and created ongoing programs to encourage participation by women in life sciences, to support diversity-equity-inclusion initiatives and to encourage student participation in the industry.  The organization also successfully led industry and organizational pivots during the COVID pandemic.  In a recent proclamation followed by an executive order issued last week, Governor Henry McMaster has formally authorized SCBIO and the state’s Commerce Department to work together to accelerate the onshoring and repatriation of the pharmaceutical industry and vital PPE products and technologies to South Carolina.

    “SCBIO has worked diligently to help South Carolina raise its profile as an emerging leader in the life sciences,” said Ms. Ford. “Our innovative companies and exceptional workforce are drivers in strengthening this industry, and we know that the life sciences will continue to play a critically important role in our state’s economic success.  Sam has been an incredible contributor to this effort, and we intend to build on our Board’s, team’s and his vision to build, advance and grow life sciences in our state.”

    Life sciences has a $12 billion economic impact in the Palmetto State, with more than 700 firms involved and over 43,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental, and agricultural biotechnology products.  It also represents a significant economic development focus for the state, with strong life science recruiting initiatives led by the South Carolina Department of Commerce and other regional economic development teams.

    South Carolina life sciences has seen a near-doubling of firms and 40% increase in life sciences’ direct employment since 2017, which combine to make it the fastest growing industry sector in the state, according to recent data provided by Dr. Joseph Von Nessen, the state's research economist and noted economic development expert with the Moore School of Business at the University of South Carolina.

    For additional information on SCBIO, please visit www.SCBIO.org.

  • sam patrick posted an article
    Life sciences company establishes diversity internship program see more

    The ISPE Foundation and Nephron Pharmaceuticals Corporation announced a partnership on the ISPE Foundation Diversity Internship Program's newest cycle to provide world-class opportunities to groups that are typically underrepresented in the pharmaceutical industry.

    Established December 2020, the pilot ISPE Foundation Diversity Internship Program received a strong response from applicants. This series with Nephron will be a 12-week experience that offers graduate and undergraduate students in their junior or senior year the opportunity to spend the summer working on priority projects for one of the fastest-growing pharmaceutical companies in the country.

    “I am delighted and honored to announce the partnership of Nephron Pharmaceuticals with the ISPE Foundation on its Diversity Internship Program,” said Antonio Moreira, PhD, ISPE Foundation Board Chair, Vice Provost, Academic Affairs, University of Maryland Baltimore County. “Over the coming years, a diverse pool of very talented students will be engaged in a variety of technologically stimulating projects under the guidance and mentorship of Nephron Pharmaceuticals scientists and engineers. These life changing experiences will inspire the interns to continue pursuing the many career opportunities that the pharmaceutical industry offers to these future leaders.”

    “We pride ourselves on two things: first, we do everything we can to make sure that everyone has a chance to achieve their dreams, and second, we utilize interns and apprentices in everything we do – they are playing key roles in our expansion and growth,” said Lou Kennedy, CEO, Nephron. “This is why I am so excited to partner with the ISPE Foundation to rollout these new internship opportunities. They represent a win-win – for participants and for our company. We are proud to invest in talented young people, and we are excited they want to invest in us. We cannot wait to get started.”

    There are currently multiple internship opportunities through the ISPE Foundation-Nephron partnership, including in the following departments:

    • Analytical Services and Formulation
    • Molecular Biology
    • Engineering

    The individuals participating in these internships will play key roles in Nephron’s ongoing projects. They will work directly with the entire Nephron team. And they will make a difference for patients across America.

    The deadline to submit is 6 May 2021. To learn more, please visit ISPEFoundation.org/Diversity-Internship-Program

    About ISPE and ISPE Foundation
    The International Society for Pharmaceutical Engineering (ISPE) is a not-for-profit association serving its 18,000+ Members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. Founded in 2017 as the philanthropic arm of ISPE, the ISPE Foundation supports education, training, and research for the advancement of innovative technologies and provides solutions to global challenges in the development, manufacture, and supply of quality pharmaceutical products for the benefit of patients around the world. To aide in this endeavor, the Foundation focuses on initiatives related to increasing the technical knowledge of the incoming workforce, fostering diversity within the industry, and supporting efforts to bring quality pharmaceutical manufacturing to new markets. Visit ISPEFoundation.org for more information.

    About Nephron Pharmaceuticals Corporation
    A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs.

    Inquiries related to the program may be directed to Foundation@ISPE.org

  • sam patrick posted an article
    FirstString Research announces new partnership with BARDA see more

    When responding to a chemical incident, mitigating long-term consequences of exposures is just as important as treating short-term injuries. BARDA and FirstString Research have partnered to repurpose Alpha-connexin Carboxyl-Terminal 1 (aCT1) eye drops as a potential medical countermeasure (MCM) against chronic eye injuries associated with sulfur mustard exposure.

    Under BARDA’s Division of Research, Innovation, and Ventures (DRIVe) Repurposing Drugs in Response to Chemical Threats (ReDIRECT) program, BARDA will provide funding for proof-of-concept studies to evaluate the therapeutic potential of aCT1 eye drops in preclinical models of sulfur mustard corneal injury. aCT1 eye drops is the second compound to be investigated as a repurposing candidate under the ReDIRECT program, a partnership between DRIVe and the Chemical, Biological, Radiological, and Nuclear (CBRN) medical countermeasures Branch.

    aCT1 is a synthetic peptide that has been shown to promote wound healing and temper pathological inflammation in the skin and eye. A topical formulation of aCT1, called Granexin® gel, is in late-stage trials (Phase 2/3) for indications of cutaneous radiation injury, cutaneous scarring from breast reduction surgery, and thermal burns.

    aCT1 eye drops decrease inflammation (a common pathological response to chemical injuries such as sulfur mustard) and may promote regenerative ocular healing. Given that aCT1 displays anti-inflammatory effects for multiple indications within the field of regenerative medicine, the therapeutic potential of an ophthalmic formulation (aCT1 eye drops) will be investigated for long-term ocular injuries caused by vesicants (blister agents), specifically sulfur mustard.

    In the aftermath of sulfur mustard exposure, acute injury to the cornea often resolves on its own within a few weeks. However, in some patients, a chronic condition may arise later once treatment stops. This delayed, recurring corneal injury, known as mustard gas keratopathy, is typically irreversible and can result in blindness. Repurposing aCT1 as an MCM against mustard gas keratopathy has the potential to improve the quality of life after chemical exposure by preventing the loss of eyesight.

    These studies will aid in establishing rapidly deployable capabilities that can be used to reduce adverse health effects following ocular exposure to sulfur mustard.

    This award is just one component of BARDA’s CBRN medical countermeasures and DRIVe’s medical countermeasures portfolios. Visit DRIVe’s ReDIRECT program to learn more.


    About FirstString Research:

    The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

    FirstString Research is an innovative biopharmaceutical company dedicated to discovering breakthrough therapies for inflammation and injury based medical conditions. The company is focused on developing and bringing to the market new therapeutic products that enable physicians to treat unmet medical needs. FirstString’s therapeutic approach aims at addressing disorders by mitigating excessive inflammation, calming the inflamed tissue, and rebooting the body’s normal injury response mechanism to enable rapid, regenerative. Learn more at https://firststringresearch.com/.

  • sam patrick posted an article
    USC adds accolades for its medical school see more

    The University of South Carolina School of Medicine Columbia is the top medical program in the country for graduates who are practicing in areas where there is a shortage of health care professionals, according to the latest U.S. News & World Report’s Best Graduate School rankings.

    The medical school’s distinction is part of the U.S. News rankings released March 30; the rankings show that UofSC is now home to more than 60 nationally ranked programs.

    Among those is the International MBA program in the Darla Moore School of Business, which retained its No. 1 ranking for the eighth consecutive year.

    “From meeting the health care needs of South Carolina’s underserved communities to preparing graduates to excel in careers in all corners of the world, these rankings demonstrate the work our faculty, staff and students do each day to improve the lives of people across the state, nation and world,” says William Tate, the university’s provost and executive vice president of academic affairs.

    The School of Medicine’s No. 1 ranking fulfills the university’s mission by providing doctors for underserved areas, sometimes referred to as “medical deserts.”

    The Columbia med school also ranks No. 45 for the number of doctors practicing in primary care specialties and No. 54 for graduates practicing direct patient care in rural areas. The School of Medicine is ranked No. 76 nationally in primary care, improving 14 spots from last year’s U.S. News rankings.

    “We are proud to be producing graduates who are committed to providing exceptional patient care to underserved communities,” says Dr. Les Hall, dean of the UofSC School of Medicine Columbia. “Our school was established to create a pipeline of quality health care professionals for South Carolina. These rankings are a clear illustration that we are achieving that mission and more.”

    The Moore School continued its reign as the highest ranked international business master’s program in the country. The International MBA has been ranked in the top three for 32 straight years.

    The university’s ranked graduate and professional programs include diverse areas of study in the sciences, humanities, technology, engineering, health sciences, law and business.

    Other highlights from the new rankings include:

     

     

    • No. 7 for school library media.
    • No. 9 for services for children and youth.
    • No. 17 for library and information studies.
    • No. 23 for criminology program.
    • No. 25 for part-time MBA.
    • No. 25 for nuclear engineering.
    • No. 25 for speech language pathology.

  • sam patrick posted an article
    Kennedy's honored for continuous service to GSSM, state see more

    The South Carolina Governor’s School for Science + Mathematics (GSSM) and its Foundation honored Lou and Bill Kennedy with the 2021 Townes Award during “Empowering STEM Leaders,” the 27th annual Townes Award Celebration, Wednesday, March 17, 6-9 p.m. at 1208 Washington Place in Columbia.

    “GSSM was honored to present the Townes Award to Lou and Bill Kennedy in recognition of their transformational leadership and commitment to empowering future generations of scientists, engineers, and innovators,” said Beth Dinndorf, executive director of the GSSM Foundation.

    “GSSM seeks out and advances our state’s most talented and motivated students,” said Danny Dorsel, GSSM Interim President and GSSM Class of 1990. “Charles Townes and Lou and Bill Kennedy are shining examples for these young minds to challenge themselves to be innovative and make a difference in our world.”

    Named for South Carolinian Dr. Charles Townes, whose visionary spirit and pioneering research led to the invention of the laser, the Townes Award recognizes individuals, businesses, and institutions that have transformed South Carolina and the world.

    “Bill and I are very deeply humbled and really excited to accept an award named in honor of an extraordinary South Carolinian who was able to achieve the Nobel Prize and the Templeton Prize, as well as many other things. This is such an auspicious group, and I’m excited to be a part of it,” Lou Kennedy said in her acceptance remarks.

    Lou and Bill Kennedy are co-owners, and Lou is the CEO, of Nephron Pharmaceuticals Corporation, a South Carolina-based company that develops and produces safe, affordable generic inhalation solutions and suspension products, including those used to treat severe respiratory distress symptoms associated with COVID-19.

  • sam patrick posted an article
    Matt Bell named to head SC Launch see more

    The South Carolina Research Authority (SCRA) has announced that Matt Bell was recently named Director of SC Launch and Executive Director of SC Launch, Inc. Bell replaces Russell Cook who resigned to focus on his recovery from a medical issue.

    A member of SCRA’s leadership team, Matt Bell is responsible for leading the strategic direction of the SC Launch program, which provides mentoring, networking, and grant funding to eligible companies that are employing new technologies within the advanced materials and manufacturing, information technology, and life science sectors. He also serves as the liaison to the SC Launch, Inc. board of directors, which makes capital investments in SCRA Member Companies that successfully complete the due diligence process. Established in 2006, SC Launch, Inc., is an independent, nonprofit corporate affiliate of SCRA.

    “Matt brings a broad background in startup creation from managing intellectual property and launching startups in academia to early-stage investing and venture capital experience. He is also an expert convener who understands how to bring the right people and resources to the table for economic development through innovation,” said Bob Quinn, SCRA Executive Director. “The SC Launch team has been accelerating the growth and success of Member Companies for many years, and Matt brings the right background and experience to lead this team as they guide our companies to becoming highly investible. We sincerely thank Russell Cook for his service to SCRA and the state, and we wish him a speedy and full recovery.”

    Prior to coming to the SCRA, Bell was managing director for Discovery Partners Institute, a University of Illinois-led initiative that leverages the state of Illinois’ university resources to drive economic development through workforce training, student immersion, and research programs. He was also a managing director and a principal with Cultivian Sandbox Venture Fund where he raised capital, managed strategic investor relationships, and managed fund activities.

    Matt Bell is a board member and advisor for Michigan State University’s state-wide, agriculture-focused translational fund, a former board member of Abcelex Technologies, and a U.S. Department of Agriculture Small Business Innovation Research grant reviewer. He earned a Master of Business Administration and a Bachelor of Science from the University of Illinois. He will be based in SCRA’s Greenville office.

    About SCRA

    https://scra.org/

    Chartered in 1983 by the State of South Carolina as a public, nonprofit corporation, South Carolina Research Authority (SCRA) fuels South Carolina’s innovation economy through the impact of its four programs. SC Academic Innovations provides funding and support to advance multi-institutional, translational research and accelerate the growth of university-based startups. SC Facilities offers high-quality laboratory and administrative workspaces for technology-based startups and academic institutions. SC Industry Solutions facilitates and funds partnerships between and among startups, industry, and academia. SC Launch mentors and funds technology-based startups that may also receive investments from SCRA’s investment affiliate, SC Launch, Inc.

  • sam patrick posted an article
    Company has processed over one million COVID tests see more

    Diversified Medical Healthcare (DMH), a holding company with four subsidiary healthcare companies, Premier Medical Laboratory Services (PMLS), CPT Medical, OnGen, and Vessel Medical, has provided leading-edge solutions to combat COVID-19 nationally, addressing supply chain gaps and infrastructure restrictions caused by the virus. Their molecular diagnostics laboratory, PMLS, became the first lab in South Carolina validated as an independent COVID-19 testing lab one year ago. Just as PMLS achieved this validation for testing shortly after the first case was reported in the US, they continue to meet demands caused by COVID-19 as they arise with their laboratory staff of over 360 employees and in-house research and development team of Ph.D. scientists. Along with large scale testing via state of the art automated lab equipment, DMH companies developed advanced software for most efficient data management, distributed customized PPE supply kits, and manufactured COVID-19 testing kits as well as viral transport medium that properly preserves specimens during transit. 

    “Since COVID-19 became a threat to our nation, we quickly streamlined our workflow, hired employees, validated various coronavirus assays, and purchased the equipment needed to test a large volume of specimens with the highest quality standards,” said Kevin Murdock founder of Diversified Medical Healthcare. “With our laboratory having one of the highest testing capacities in the nation, an in-house medical manufacturing firm, a lab equipment company, and data management software company, we feel that it’s imperative to do our part to help keep the country open and our citizens safe.”

    At this one year mark, PMLS has processed over one million (1,000,000) tests to determine COVID-19 results for patients nationwide. With their highly advanced laboratory information management system (LIMS) created by OnGen, data is communicated directly from high throughput laboratory equipment for fast, accurate storage and delivery of data to healthcare providers and patients. Many of PMLS’ lab processes are automated to allow them a testing capacity of 300,000 tests per day. With this scalability, PMLS has enabled other laboratories and testing sites to increase their testing capacity and turnaround of results with Virtual Lab. An innovative COVID-19 testing solution to overcome laboratory infrastructure restrictions, Virtual Lab allows these facilities to utilize PMLS’ fully-automated robotic workflow and team of 360 employees to largely increase their testing capacity and efficiency while bypassing the need to purchase new equipment or endure waiting time of weeks or more for shipping, installation, and validation. Along with helping other labs, hospital systems and large organizations to test more patients, Diversified Medical Healthcare has donated hundreds of thousands of masks to local law enforcement, paramedics, fire departments, hospitals, and the Shriners organization and has provided free testing to first responders during the pandemic.

    As another means to aid laboratories, healthcare systems, and large organizations in the expansion of their COVID-19 testing, Vessel Medical offers Lab in a Box, turnkey lab equipment that comes with everything needed for professional laboratory level diagnostics for COVID-19, Flu A and B, upper respiratory, STD/UTI, cancer risk screening, pharmacogenomics, and antibiotic resistance testing. Developed by leading scientists and technicians in partnership with Hamilton Company, Thermo Fisher, and Grenova, Lab in a Box enables a high capacity of onsite diagnostics for hospitals, expanding laboratories, schools, and large companies in need of quick and accurate testing results. With precision robotic instruments, lab in a box includes high throughput liquid handling along with automated, custom-programmable pipetting that decreases human error and result turnaround time.

    Another DMH company, CPT Medical, shifted their production of surgical supplies to include manufacturing of COVID-19 testing kits since the beginning of the pandemic. CPT Medical is now capable of manufacturing 60,000 test kits per day and works in conjunction with PMLS to offer customizable testing to large organizations. Some of the large organizations that PMLS has partnered with as the official COVID-19 testing lab are the United Soccer League (USL) and Division I/Division II teams in 7 collegiate conferences as well as large schools and business organizations across the US. PMLS is also the processing lab for Human Health Services surge sites and state health departments in South Carolina, Arizona, Utah, and North Carolina and is the Blue Cross Blue Shield preferred COVID-19 testing lab in Texas, South Carolina, and North Carolina. Through all of these partnerships, PMLS has continued in their reputation of delivering the most advanced testing with rapid, reliable results, and diligent customer care.

    Now, as vaccines are administered and restrictions on social distancing are being lifted, PMLS is conducting a critical large scale genomic sequencing for the surveillance of new COVID-19 variants, taking proactive measures so that a future surge of a mutated Sars CoV-2 strain is less likely to occur. The data collected from genomic sequencing can help pharmaceutical companies to stay ahead of the variants and make any changes needed to the current vaccines and treatments for higher efficacy and best patient outcomes. With PMLS’ high throughput genomic sequencers and library prep instruments that automate the library prep and sequencing process, a much higher capacity for genomic sequencing is achieved and margins of human error are drastically reduced. By sequencing an exponentially higher amount of specimens, PMLS is better equipped to provide meaningful analysis with larger amounts of data and faster turnaround times for the effective surveillance of SARS-CoV-2. PMLS is in discussions with the CDC and multiple states across the nation to provide COVID sequencing services at ports of entry and local and regional hotspots.  Along with this and their previous accomplishments, more groundbreaking COVID-19 solutions by Diversified Medical Healthcare are soon to be announced.

    For more information, please visit www.divmedinc.com or call 866-521-7541.

  • sam patrick posted an article
    Softbox a key player in battle to beat COVID see more

    Softbox, a leading global innovator and provider of passive temperature control packaging solutions for the pharmaceutical, life science and cold chain logistics industries, is proud to support Pfizer in the distribution of Covid-19 vaccines through the supply of a high-performance temperature-controlled parcel shipper developed specifically for ultra-low temperature applications.

    Softbox supported Pfizer with the development of the highly specialised and reusable ultra-low temperature (ULT) shipper to help them on the distribution of ultra-low temperature vaccines and storing them at Point of Use (POU) sites.  

    Ultra-Low Temperature vaccines, such as that developed by Pfizer – BioNTech, uses mRNA (messenger RNA) technology and must be stored at temperatures between -90°C to -60°C to ensure that the vaccine’s quality and efficacy is maintained. The ULT shipper is capable of maintaining the required temperature during shipping of Covid-19 vaccines between -90°C to -60°C for at least 10 days unopened.

    The highly innovative shipper utilises high performance insulation materials, incorporated in a robust and reusable construction, in conjunction with dry ice, to ensure long term ultra-low temperature control. Based on current guidelines, the Softbox ULT Shipper can be opened twice a day, for up to three minutes at a time. This allows clinicians at Point of Use (POU) sites to access the vaccine vials required for each day’s immunisation clinics without exposing the remaining vaccine stored within the shipper to ambient temperatures, thus ensuring integrity of the vaccine is maintained.

    When correctly managed, the ULT Shipper can be used to store vaccines for in excess of 30 days. Through a process called “Re-Icing” the dry ice in the Softbox ULT Shipper can be topped up ensuring maximum thermal protection of the highly temperature sensitive mRNA vaccines.

    “Softbox’s extensive knowledge and experience in temperature control packaging solutions and the cold chain industry was the right choice for us. They immediately understood the unprecedented task at hand that was in front of us with the distribution of the vaccine, and quickly started to work with us to develop a unique packaging system that does not waste any precious vaccine and creates a seamless experience for customers.” said Tanya Alcorn, Vice President, Biopharma Global Supply Chain for Pfizer. “Their technical capabilities and innovative approach helped us achieve an excellent result in a very short period of time.”

    Kevin Valentine, CEO of Softbox, said: “We are immensely proud to be playing such an important role in the fight against Covid-19. We worked extremely hard during 2020 to help Pfizer develop this highly innovative ULT shipper; establishing one of the world’s largest fleets of reusable temperature-controlled parcel shippers in the process and setting up two world-class service centres to support ULT shipper refurbishment.”

    “It’s a huge honour to have the opportunity to support the distribution of these vital vaccines at the right temperature, maintain their integrity and help save millions of lives.” 

    For more information about Softbox visit: www.softboxsystems.com

    About Softbox
    Softbox is an award-winning temperature control packaging innovator that has been designing and producing high performance passive temperature control packaging solutions for over 20 years. We offer consistent quality to our clients from our strategically located global manufacturing sites throughout Europe, North America, Latin America, India and Asia Pacific.

    We have formed long standing partnerships with the world’s leading pharmaceutical, clinical research, biotech and logistics companies, and apply innovative thinking to overcome the challenges that our clients face in managing the Cold Chain when shipping temperature sensitive clinical trial and commercialised products.

    For more information about Softbox visit: www.softboxsystems.com

  • sam patrick posted an article
    Rockwell to lead growth strategy at PAI see more

    Pharmaceutical Associates, Inc. (PAI) today announced the appointment of Brandon Rockwell as Chief Operating Officer, bringing 15 years of business development experience to the company. In his new role, Rockwell will oversee PAI’s growth strategy, further solidifying the company’s position as the number one manufacturer of quality liquid pharmaceuticals in the US.

    Rockwell has led teams in business development and strategy, portfolio management, and project management for nearly 15 years, most recently as Senior Vice President of Business Development and Strategy for Endo, where he was responsible for the generic, hospital, and branded divisions. Prior to that, he worked for Par Pharmaceutical where he led the Business Development and Licensing function. In this role, he helped shape the strategic direction of the company through its acquisitions of Edict, Anchen, JHP and the integration between Qualitest and Par.

    Under Rockwell’s tutelage, PAI will implement more advanced strategies and continue to revolutionize the space of unit dose medicine and liquid pharmaceuticals so they can meet the ever-growing number of healthcare facilities that PAI serves.

    For more information about Pharmaceutical Associates Inc., please visit www.paipharma.com.

     

    About Pharmaceutical Associates, Inc.

    Among North America’s leaders in quality, safety, and productivity, Pharmaceutical Associates Inc. (PAI) manufactures and markets generic liquid pharmaceuticals. PAI has been at the forefront of producing better-targeted suspensions, oral solutions, elixirs, syrups, and liquids for nearly 50 years. To meet the unique needs of retail chains and independent pharmacies, hospitals, long-term care facilities, and government agencies, PAI offers standard bottle packaging and ready-to-dispense packaging. In fact, PAI was the first independent manufacturer to develop vertically integrated unit-dose (UD) packaging and the first to offer complete lines of hard-to-find liquid products in both out-patient and UD packaging.

  • sam patrick posted an article
    Orangeburg, SC bio-ag facility included as part of acquisition see more

    Syngenta Group has announced the acquisition of Valagro, a leading Biologicals company, by its business unit Syngenta Crop Protection. The investment positions Syngenta Crop Protection as one of the key global companies poised to shape the rapidly growing Biologicals market, which is set to nearly double in size over the next five years. Valagro will continue to operate as an independent brand in the market within the Syngenta Crop Protection business.

    Valagro, a leader in the development, production and marketing of biostimulant and advanced nutrient solutions for cash and row crops, began construction of its Orangeburg, South Carolina plant in October 2019 with a groundbreaking ceremony, which was attended by members of the local community, esteemed guests, state representatives, as well as members of federal government.  Consistent with Valagro’s commitment to innovation, the now-operational plant has introduced cutting-edge technologies for the production of plant biostimulants and chelated micronutrients in the United States. The opening of the production site also created nearly 50 new advanced manufacturing jobs.

    Valagro is a market-leading producer of innovative Biologicals, with a ~10% CAGR from 2009-2019 and an approximate revenue of $175m in 2019. The company has excelled by harnessing the power of nature to provide innovative and effective solutions for plant nutrition and care. With 40 years of experience, it offers its customers a comprehensive crop portfolio in Biologicals with a market-leading position in biostimulants and speciality nutrients. Headquartered in Atessa, Italy, Valagro serves customers around the world with a strong presence in Europe and North America, as well as a growing footprint in Asia, including China, and LATAM. Valagro has over 700 employees, 13 subsidiaries and 8 production sites around the world, with a portfolio backed by best-in-class biological R&D, production and commercialization capabilities.

    This strategic acquisition enables Syngenta Crop Protection to build a world-leading Biologicals business. Valagro has a strong commercial and production standing, as well as an industry-leading technology and research capacity. Valagro's well-established portfolio in biostimulants and specialty nutrients will complement both Syngenta Crop Protection's current range of biostimulants and biocontrols, as well as its future pipeline of biological solutions. Biocontrols and biostimulants, natural solutions for pest, disease control and crop improvement, are increasingly important for farmers worldwide in their efforts for sustainable agricultural production. This acquisition is fully in-line with Syngenta Crop Protection’s strategy to provide growers with additional complementary choices of products and technologies in order to effectively and sustainably care for their crops by managing resistance, enhancing soil health, reducing residues in crops, and addressing consumer demands.

    Erik Fyrwald, CEO of Syngenta Group stated: “We are looking forward to welcoming the Valagro team to Syngenta Group. This acquisition underlines our growth ambitions in this area and positions us as one of the strongest players in the global biologicals market. The investment also forms part of our $2 billion commitment to help farmers address the effects of climate change and improve agricultural sustainability as part of our Good Growth Plan.”

    Giuseppe Natale, CEO Valagro said: “For 40 years our mission at Valagro has been to harness nature in order to help farmers achieve higher yields and grow better quality crops. This agreement will open up new, previously unimaginable growth prospects for the Valagro group worldwide. Now that we are part of a company with the resources and ambition of Syngenta Crop Protection, we have exciting new opportunities for our innovation to better deliver even more options for farmers and to invest even more effectively in the sustainable future of agriculture.”

    Jon Parr, President Global Crop Protection at Syngenta noted: “Significant levels of investment in innovations such as Biologicals are necessary in order to deliver a sustainable future and help farmers deliver a food system working in harmony with nature. Syngenta Crop Protection and Valagro have a foundation in science-based innovation and are eager to collaborate, share knowledge and build on each other’s capabilities. By fostering the entrepreneurial spirit and culture of Valagro, powered by our global scale and capability, together we will shape the future of the agricultural Biologicals market.”

    The financial terms of the transaction are not disclosed.

    About Syngenta Group

    Syngenta Group is one of the world’s leading agriculture innovation companies, with roots going back more than 250 years. Its 48,000 people across more than 100 countries strive to transform agriculture through breakthrough products and technologies that play a vital role in enabling the food chain to feed the world safely, sustainably and with respect for our planet. Swiss headquartered and Chinese-owned, the Group draws strength from its four business units – Syngenta Crop Protection headquartered in Switzerland, Syngenta Seeds headquartered in the United States, ADAMA headquartered in Israel, and Syngenta Group China – that provide industry-leading ways to serve customers everywhere.

  • sam patrick posted an article
    SCBIO, United Community Bank to sponsor development program see more

    Furman University’s Women’s Leadership Institute (WLI) will be presented virtually this year with two statewide community partners supporting the effort. United Community Bank will be the program’s presenting sponsor and SCBIO has signed on to be a presenting partner.

    The WLI is a seven-week leadership development program open to emerging and established women leaders in South Carolina, with past participants from every corner and many industries of the Palmetto State. It is led by distinguished Furman faculty and expert facilitators from civic and corporate organizations who cover core competencies from team leadership and design thinking to negotiating and developing networks.

    The program this year will comprise live, virtual sessions on Tuesdays and Thursdays, from 11:30  a.m. to 1:00 p.m. EST, beginning April 15 and ending June 1. The cost is $1,499 and registration is open now. For more information, or to nominate someone for participation, visit the WLI website.

    “The Women’s Leadership Institute at Furman is a wonderful opportunity to network with other female leaders in the community, learn more about my own natural strengths and abilities, and discover how I can use my voice to be an advocate for change in our local community,” says Jessica McCoy, a 2020 WLI graduate.

    “I would recommend this program to anyone who is actively seeking to make a difference in every area of their life. I promise you won’t regret a single second of it,” said McCoy, the business development manager for Brasfield and Gorrie, one of the country’s largest privately held construction companies.

    “The Women’s Leadership Institute has a long history of helping women succeed in their chosen careers and in life,” said Elizabeth Davis, Furman University president. “We are excited to have two cornerstone organizations join us this year to help extend our leadership training and advance equality, equity and diversity in the workplace.”

    Furman’s WLI began in 1998, and has helped more than 600 women from diverse sectors develop their leadership skills that are essential to advancing within their organizations.

    “Having United Community Bank and SCBIO join as presenting sponsor and presenting partner, respectively, increases the breadth and depth of the program into South Carolina’s business community,” says Anthony Herrera, executive director of Furman’s Institute for Innovation and Entrepreneurship.

    “United Community Bank is committed to making a difference in our community and we believe that is achieved through sponsoring programs that support the development of those who serve others,” said Moryah Jackson, vice president of community development and engagement for United Community Bank. “We are excited to be this year’s presenting sponsor and provide women with a professional development opportunity that will help them go out and make the world a better place.”

    “Furman’s Women’s Leadership Institute is among the premier programs in the Southeast devoted to promoting talent development, fostering invaluable connections and expanding new opportunities for current and emerging women leaders across the business ecosystem,” said Erin Ford, executive vice president and chief operating officer for SCBIO. “We are honored and enthusiastic supporters of the WLI program and mission, and look forward to being actively involved in this fantastic program.”

    Ford and Sam Konduros, chief executive officer and president of SCBIO, will present during one session, and a panel from United Community Bank will close the program on June 1.

  • sam patrick posted an article
    Executive Partnering, Virtual Exhibit Hall Add Draw for Power of Us Conference Feb. 16-17 see more

    With conference registration surging more than 20% past prior record levels and the addition of a “singularly significant innovation announcement focused on cancer treatments and precision medicine advancement”, SCBIO's “The Power of Us”  virtual conference Feb. 16-17 is preparing for its largest gathering ever next week... delivered virtually to registrants from across the Palmetto State plus 25 states and 8 countries.

    Adding to the excitement is a just-scheduled “major innovation announcement” by a South Carolina company, in tandem with West Coast and German allies, that has significant implications for cancer diagnosis and treatment on a global level, organizers say.

    Already in excess of 500 registrants from across America and around the globe, the acclaimed SCBIO conference – the annual gathering of South Carolina’s life sciences community – will also celebrate the rapid growth of the industry and the contributions of its 800+ organizations in helping America and the world overcome the brutal COVID-19 pandemic.

    South Carolina life sciences has seen a doubling of firms and 40% increase in life sciences’ direct employment since 2017, which combine to make it the fastest growing industry sector in the state, according to recent data provided by Dr. Joseph Von Nessen, the state's research economist and noted economic development expert with the Moore School of Business at the University of South Carolina.

    “Dr. Von Nessen’s data validates that the life sciences industry in South Carolina is experiencing stunning growth, thanks to the combined efforts of our state’s economic development teams, industry partners, research universities, elected officials and other partners,” said SCBIO CEO Sam Konduros.  “It’s an exciting time to be a part of an industry that is saving lives and improving quality of care.”

    The industry has a $12+ billion economic impact in the Palmetto State, with more than 800 firms located in 42 of 46 counties across the state and over 43,000 professionals employed directly or indirectly in research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.

    Organizers are tight-lipped about the Innovation Announcement details, which will be unveiled at 8:30 a.m. on the second day of the conference—February 17. 

    “We will say that the implications of the announcement include a new technology that has the ability to detect cancers at the earliest time ever, to further lifespans, and to unlock a new era of precision medicine, ” said Mr. Konduros.

    Adding to the draw of the conference are scores of organizations from across America showcasing their capabilities in a virtual exhibit hall, direct 1-to-1 executive meetings on demand via a Partnering Portal, major industry awards and – naturally – top speakers.

    Committed presenters include BIO Global CEO Dr. Michelle McMurry-Heath; Microsoft Vice President Jamie Harper, who leads the global team supporting higher education and K-12 initiatives; and Bill Stadtlander, Commercial Leader of Verily, the Google subsidiary focused on life sciences and use of health data and AI to improve lives.

    Also speaking at SCBIO 2021 are Courtney Christian, Senior Director of Policy and Research at PhRMA and former leader of the Black Women's Health Imperative; Dr. Harris Pastides, former USC President and outgoing chair of the SC Institute of Medicine and Public Health; Dr. Pat Cawley, CEO of MUSC Health; and Dr. Marjorie Jenkins, Dean of the USC School of Medicine - Upstate and Chief Academic Officer of Prisma Health Upstate, among others.

    Themed “The Power of Us,” the 2-day SCBIO 2021 virtual event will feature sessions on The Power of Innovation, The Power of Partnership, and The Power of People – each a fundamental force which drives the state’s surging $12 billion industry that is a key contributor to South Carolina’s expanding knowledge economy.

    The conference will also feature SCBIO CEO Sam Konduros delivering the “State of South Carolina’s Life Sciences Industry” address, and release of SCBIO’s 2020 annual report

    Leaders already registered to attend include executives from Presenting Sponsor Vikor Scientific, Champion Sponsor Nephron Pharmaceuticals, Keynote Sponsor Medpoint, Pinnacle Awards Sponsor Softbox and others.  Leading biotech and med-tech industry brands participating include BIO, Johnson & Johnson, AVX, PhRMA, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, ZEUS, Patheon Thermo Fisher, Zverse, Abbott, Alcami, SSOE – Stevens & Wilkinson, and more.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, the South Carolina Department of Commerce, SCRA, South Carolina Hospital Association and others.

    Registration is open online at the 2021 Virtual Conference section of www.scbio.org.  Registration is free to employees of most SCBIO investors and supporters as well as to students interested in life sciences careers, while faculty and teachers can attend the entire conference for $25.  General admission tickets are available for as little as $75.  Virtual Exhibit  space and sponsorships are also available by inquiring at info@scbio.org.

    For additional information on SCBIO or to register for SCBIO 2021, visit www.SCBIO.org.

  • sam patrick posted an article
    SCBIO, industry honored by Governor during record-setting virtual annual conference see more

    South Carolina Gov. Henry McMaster

    Proclamation – Feb. 15, 2021

     

    WHEREAS, South Carolina has cultivated a cutting-edge life sciences sector with an annual economic impact of more than $12 billion dollars; and

    WHEREAS, more than 800 firms and over 43,000 professionals are directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products; and

    WHEREAS, since 2017, the life sciences sector has become South Carolina's fastest- growing industry, with employment growing at double the rate of South Carolina's economy as a whole; and

    WHEREAS, SCBIO is the organization exclusively focused on attracting new life science sector jobs and investment to South Carolina; and

    WHEREAS, during the COVID-19 pandemic, more than 100 life sciences organizations across South Carolina worked together to support and promote the procurement and distribution of personal protective equipment, support and implement COVID-19 testing and expedite health solutions for our citizens; and

    WHEREAS, in collaboration with the South Carolina Department of Commerce and SCBIO, South Carolina's economic development recruitment efforts shall include an enhanced emphasis and focus on attracting, building, advancing, innovating and growing existing and new life sciences businesses in the state.

    NOW, THEREFORE, I, Henry McMaster, Governor of the great State of South Carolina, do hereby proclaim February 15-19, 2021, as

    SCBIO LIFE SCIENCE WEEK

    throughout the state and encourage all South Carolinians to recognize and appreciate the many contributions of the life sciences industry to South Carolina's health and economic prosperity.

  • sam patrick posted an article
    Governor salutes industry during record-setting SC Life Sciences Conference see more

    SOUTH CAROLINA – February 16, 2021 – In recognition of the importance of the life sciences industry in South Carolina, Governor Henry McMaster today issued a proclamation recognizing February 15-19, 2021 as South Carolina Life Sciences Week in the Palmetto State.

    Governor McMaster made the announcement just steps from where SCBIO organizers were putting the finishing touches on Day 1 of the largest-ever life sciences gathering held – virtually of course -- in the state.  A record 600 registrants from across America and around the globe are attending the virtual SCBIO gathering of South Carolina’s life sciences community – and celebrating the contributions of its 800+ organizations in helping America and the world overcome the challenging COVID-19 pandemic.

    “South Carolina has developed a strong reputation as an emerging leader in the life sciences,” said Governor McMaster. “Our innovative companies and exceptional workforce are key drivers in strengthening our economy and creating new opportunities for South Carolinians. With an incredible pace of growth in the industry here, we know that the life sciences will continue to play a critically important role in our state’s economic success for generations to come.”

    Governor McMaster made the proclamation in downtown Greenville, in the heart of the county which possesses the state’s largest concentration of life sciences companies, although the industry boasts life sciences organizations in 42 of South Carolina’s 46 counties currently.  Governor McMaster was flanked by leadership and Board members of SCBIO, South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, innovating and growing the life sciences industry in the state. 

    Life sciences has a $12 billion economic impact in the Palmetto State, with more than 800 firms involved and over 43,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.  It also represents a significant economic development focus for the state, with strong life science recruiting initiatives led by the South Carolina Department of Commerce and other regional economic development teams.

    South Carolina life sciences has seen a doubling of firms and 40% increase in life sciences’ direct employment since 2017, which combine to make it the fastest growing industry sector in the state, according to recent data provided by Dr. Joseph Von Nessen, the state's research economist and noted economic development expert with the Moore School of Business at the University of South Carolina.

    “Life sciences is a major driver of South Carolina’s economy today, and this conference is testament to the industry’s surging impact, reach and rapidly rising economic significance in our state and country,” noted SCBIO President and CEO Sam Konduros. “We’re honored by Governor McMaster’s recognition, and appreciate his personal support for the contributions that life sciences are making to improve quality of life, care and economic standing for South Carolina citizens.”

    For additional information on SCBIO or to register for SCBIO 2021, visit www.SCBIO.org.